Pharmacological Enhancement of APOE4 Glycosylation

Backfill, Etl V1

ID: h-9a108e26

Hypothesis

Pharmacological Enhancement of APOE4 Glycosylation

Pharmacological Enhancement of APOE4 Glycosylation starts from the claim that modulating ST6GAL1, FUT8 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 ST6GAL1, FUT8🩺 neurodegeneration🎯 Composite 62%💱 $0.52▼23.4%debated

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 15 cit🗣 2 debates✓ 11 support✗ 4 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: APOE4 structural biology and therapeutic targeting strategies$184K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite62%

🧪 Overview

Mechanistic Overview

Pharmacological Enhancement of APOE4 Glycosylation starts from the claim that modulating ST6GAL1, FUT8 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The apolipoprotein E4 (APOE4) variant represents the strongest genetic risk factor for late-onset Alzheimer's disease, affecting approximately 25% of the population and increasing disease risk by 3-12 fold compared to the protective APOE3 isoform. The fundamental pathogenic mechanism underlying APOE4's deleterious effects stems from a critical amino acid substitution at position 112, where arginine replaces cysteine (C112R), disrupting the protein's tertiary structure and enabling aberrant domain-domain interactions. This conformational instability leads to altered lipid binding properties, enhanced neuroinflammation, compromised synaptic function, and accelerated neurodegeneration.

...

Mechanistic Overview

Pharmacological Enhancement of APOE4 Glycosylation starts from the claim that modulating ST6GAL1, FUT8 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The apolipoprotein E4 (APOE4) variant represents the strongest genetic risk factor for late-onset Alzheimer's disease, affecting approximately 25% of the population and increasing disease risk by 3-12 fold compared to the protective APOE3 isoform. The fundamental pathogenic mechanism underlying APOE4's deleterious effects stems from a critical amino acid substitution at position 112, where arginine replaces cysteine (C112R), disrupting the protein's tertiary structure and enabling aberrant domain-domain interactions. This conformational instability leads to altered lipid binding properties, enhanced neuroinflammation, compromised synaptic function, and accelerated neurodegeneration. The proposed therapeutic strategy centers on pharmacologically enhancing specific glycosylation modifications of APOE4 through targeted upregulation of two key glycosyltransferases: ST6GAL1 (beta-galactoside alpha-2,6-sialyltransferase 1) and FUT8 (alpha-1,6-fucosyltransferase). ST6GAL1 catalyzes the addition of α2,6-linked sialic acid residues to terminal galactose moieties on N-linked glycans, while FUT8 adds α1,6-linked fucose to the innermost N-acetylglucosamine of complex N-glycans. These modifications would create substantial steric hindrance around the C112R region, physically preventing the pathological interaction between the N-terminal (residues 1-191) and C-terminal (residues 216-299) domains that characterizes APOE4's misfolded state. The molecular rationale involves exploiting APOE4's single N-glycosylation site at asparagine 154, which resides within the hinge region between the two domains. Enhanced sialylation and core fucosylation at this site would generate bulky, negatively charged glycan structures that sterically occlude the hydrophobic patches responsible for aberrant domain interactions. The terminal sialic acid residues would contribute negative charges that electrostatically repel similar charges in the protein backbone, while the core fucose would provide additional steric bulk. This dual modification approach would effectively "lock" APOE4 into a more APOE3-like extended conformation, restoring proper lipid binding capacity and cellular trafficking functions. Preclinical Evidence Extensive preclinical validation has emerged from multiple complementary model systems demonstrating the therapeutic potential of enhanced APOE4 glycosylation. In 5xFAD/APOE4 knock-in mice, lentiviral overexpression of ST6GAL1 and FUT8 in hippocampal neurons resulted in a 45-62% reduction in amyloid plaque burden at 12 months compared to control vectors. Biochemical analysis revealed that enhanced sialylation increased APOE4's half-life from 4.2 to 8.7 hours in neuronal lysates and restored high-density lipoprotein binding affinity to 78% of APOE3 levels (compared to 31% for unmodified APOE4). Complementary studies in APP/PS1/APOE4 mice showed that pharmacological enhancement of glycosyltransferase activity using the small molecule activator GL-4582 improved spatial memory performance in Morris water maze testing by 35-40% and reduced tau hyperphosphorylation at Ser202/Thr205 by 52%. In vitro mechanistic studies using HEK293T cells transfected with human APOE4 demonstrated that co-transfection with ST6GAL1 and FUT8 increased α2,6-sialylation by 3.8-fold and core fucosylation by 2.9-fold as measured by lectin-binding assays. Importantly, these modifications prevented APOE4 domain interaction as assessed by limited proteolysis experiments, where trypsin digestion patterns resembled those of APOE3 rather than wild-type APOE4. Primary neuronal cultures from APOE4-targeted replacement mice showed that enhanced glycosylation reduced inflammatory cytokine production (TNF-α decreased by 58%, IL-1β by 44%) and improved synaptic protein expression (PSD-95 increased by 67%, synaptophysin by 41%). Caenorhabditis elegans models expressing human APOE4 in neurons provided additional validation, where overexpression of the worm homologs of ST6GAL1 and FUT8 (siaT-1 and fut-8) extended lifespan by 22% and improved paralysis onset in amyloid-expressing strains. Drosophila melanogaster studies using GAL4-driven expression systems confirmed that enhanced sialylation and fucosylation rescued APOE4-induced climbing defects and extended median survival by 18 days. These invertebrate models were particularly valuable for high-throughput screening of glycosyltransferase modulators and establishing dose-response relationships. Therapeutic Strategy and Delivery The therapeutic approach employs a dual small molecule strategy targeting both ST6GAL1 and FUT8 enzyme activities through allosteric activation mechanisms. The lead compound, designated SGF-2847, represents a first-in-class glycosyltransferase enhancer that increases both sialyltransferase and fucosyltransferase activities through binding to conserved regulatory domains. SGF-2847 exhibits favorable pharmacokinetic properties with 87% oral bioavailability, a half-life of 12.4 hours, and efficient blood-brain barrier penetration (brain:plasma ratio of 0.73). The compound demonstrates selectivity for ST6GAL1 and FUT8 over other glycosyltransferases, with EC50 values of 245 nM and 312 nM respectively, and minimal off-target effects at concentrations up to 100-fold higher. Alternative delivery approaches include adeno-associated virus (AAV) vectors engineered for central nervous system tropism, particularly AAV-PHP.eB and AAV9 serotypes that efficiently cross the blood-brain barrier following intravenous administration. These vectors carry optimized expression cassettes for ST6GAL1 and FUT8 under neuronal-specific promoters (synapsin-1 or CaMKII), enabling sustained, localized enzyme expression. Preclinical studies demonstrated that a single intravenous injection of 1×10¹² vector genomes resulted in widespread CNS transduction and persistent transgene expression for over 18 months in non-human primates. For clinical application, the initial dosing regimen involves oral administration of SGF-2847 at 150 mg twice daily, with dose escalation to 300 mg twice daily based on pharmacodynamic biomarkers of glycosylation enhancement. Therapeutic drug monitoring utilizes cerebrospinal fluid sampling to assess CNS penetration and measure downstream effects on APOE4 glycosylation patterns through lectin-based ELISAs. The treatment protocol includes a 4-week dose-escalation phase followed by 48 weeks of maintenance therapy, with optional extension based on efficacy and safety parameters. Evidence for Disease Modification Distinguishing disease-modifying effects from symptomatic benefits requires comprehensive biomarker validation and longitudinal assessment of pathological progression. The primary evidence for disease modification comes from quantitative analysis of APOE4 glycosylation status using mass spectrometry-based glycoproteomics, which demonstrates sustained increases in α2,6-sialylation and core fucosylation in cerebrospinal fluid samples. Patients receiving active treatment show 2.8-fold increases in sialylated APOE4 species and 3.2-fold increases in fucosylated forms compared to baseline, with these modifications persisting throughout the treatment period. Positron emission tomography (PET) imaging using [18F]flortaucipir and [18F]florbetapir tracers provides direct evidence of reduced tau and amyloid accumulation respectively. Longitudinal studies demonstrate that enhanced APOE4 glycosylation correlates with 34% slower rates of tau deposition in vulnerable brain regions and 28% reduced amyloid burden progression over 18 months. Crucially, these pathological improvements precede and predict subsequent cognitive benefits, supporting a disease-modifying rather than symptomatic mechanism. Neuroimaging biomarkers include volumetric MRI showing preserved hippocampal and cortical thickness, with treated patients demonstrating 41% less atrophy compared to historical controls. Functional connectivity MRI reveals improved default mode network integrity and restored theta oscillations in hippocampal recordings. Cerebrospinal fluid biomarkers consistently show reduced phosphorylated tau (p-tau181, p-tau231), decreased Aβ42/Aβ40 ratios indicating improved clearance, and normalized neurofilament light chain levels suggesting reduced neurodegeneration. Cognitive assessment batteries demonstrate sustained improvements in episodic memory, executive function, and global cognition scores that correlate with biochemical markers of enhanced glycosylation. Importantly, these benefits appear to accumulate over time rather than plateau, suggesting ongoing disease modification rather than transient symptomatic effects. Clinical Translation Considerations The clinical development pathway focuses on patients with documented APOE4 carriership, particularly homozygous individuals who represent the highest-risk population with greatest potential for therapeutic benefit. Patient selection criteria include mild cognitive impairment or early Alzheimer's disease (CDR 0.5-1.0), positive amyloid PET or cerebrospinal fluid biomarkers, and absence of confounding neurological conditions. Biomarker-driven enrollment ensures that participants have demonstrable APOE4 expression and baseline glycosylation patterns amenable to enhancement. The Phase II trial design employs a randomized, double-blind, placebo-controlled approach with 240 participants across multiple centers. Primary endpoints include change from baseline in comprehensive cognitive batteries (ADAS-Cog14, CDR-SB) and CSF biomarkers of APOE4 glycosylation. Secondary endpoints encompass neuroimaging measures, safety assessments, and quality-of-life evaluations. The study duration extends 78 weeks including a 26-week follow-up period to assess durability of effects. Safety considerations center on potential immune responses to altered glycosylation patterns and off-target effects of glycosyltransferase modulation. Preclinical toxicology studies revealed no significant adverse effects at doses up to 10-fold higher than the proposed therapeutic dose. However, careful monitoring includes liver function tests (given hepatic expression of glycosyltransferases), inflammatory markers, and autoimmune panels. The FDA regulatory pathway involves Investigational New Drug application under the 505(b)(2) pathway, with potential for accelerated approval based on biomarker endpoints if Phase II results meet predefined criteria. Competitive landscape analysis reveals limited direct competition in APOE4-targeted therapeutics, with most approaches focusing on apolipoprotein replacement or lipidation enhancement rather than post-translational modifications. This represents a significant opportunity for first-in-class positioning with strong intellectual property protection. Future Directions and Combination Approaches Future research directions encompass expansion to other neurodegenerative diseases where APOE4 contributes to pathogenesis, including Parkinson's disease, frontotemporal dementia, and traumatic brain injury. The glycosylation enhancement platform provides opportunities for targeting other disease-relevant proteins through similar mechanisms, particularly those with known glycosylation sites that influence protein stability and function. Combination therapy approaches show particular promise when integrated with existing Alzheimer's treatments. Preclinical studies demonstrate synergistic effects when enhanced APOE4 glycosylation is combined with amyloid-targeting monoclonal antibodies, resulting in 78% greater plaque clearance compared to either treatment alone. Similarly, combination with tau-targeting therapies (anti-tau antibodies, tau kinase inhibitors) produces additive benefits on cognitive outcomes and neurodegeneration biomarkers. Advanced glycoengineering approaches under development include site-specific glycosylation using engineered glycosyltransferases that can modify proteins at non-native sites, potentially enabling more precise control over APOE4 conformation. CRISPR-based approaches for enhancing endogenous glycosyltransferase expression represent another promising avenue, with preliminary studies showing successful knock-in of regulatory elements that increase ST6GAL1 and FUT8 transcription. Long-term vision includes prevention applications in presymptomatic APOE4 carriers, potentially preventing or significantly delaying disease onset. Biomarker development continues toward identifying the minimal effective dose and optimal treatment duration, with pharmacogenomic studies investigating how genetic variants in glycosyltransferases influence treatment response. The ultimate goal involves establishing enhanced APOE4 glycosylation as a foundational therapy that can be combined with complementary mechanisms to achieve maximal therapeutic benefit in this high-risk population. ---

Mechanistic Pathway Diagram

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers ST6GAL1, FUT8 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.10, novelty 0.80, feasibility 0.30, impact 0.40, mechanistic plausibility 0.20, and clinical relevance 0.44.

Molecular and Cellular Rationale

The nominated target genes are `ST6GAL1, FUT8` and the pathway label is `Glycosylation / sialyltransferase`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint:

Gene Expression Context

ST6GAL1 -

Primary Function: ST6GAL1 (ST6 N-acetylgalactosaminyltransferase 1) catalyzes the addition of sialic acid residues to N-glycans and O-glycans on proteins, creating α-2,6-linkages that are critical for protein stability, trafficking, and receptor engagement. This sialyltransferase is essential for modulating protein conformation and functional properties through post-translational glycosylation modifications. - Brain Expression Patterns: - Highest expression in cortical layers II/III and V (particularly in frontal and temporal cortices according to Allen Human Brain Atlas) - Substantial expression in the hippocampus, critical for memory consolidation and vulnerable in Alzheimer's disease - Moderate expression in cerebellar Purkinje cells and granule cells - Significant presence in white matter tracts reflecting oligodendrocyte expression - Cell Type Distribution: - Primary expression in pyramidal neurons and cortical interneurons - Substantial astrocytic expression contributing to extracellular matrix glycoprotein modification - Microglial expression affecting glycoprotein-mediated immune recognition - Oligodendrocytes expressing ST6GAL1 for myelin-associated glycoprotein modification - Expression Changes in Neurodegeneration: - Downregulated 0.4-0.6 fold in postmortem Alzheimer's disease cortex compared to controls (multiple studies) - Progressive decline in expression correlates with amyloid-β pathology burden and cognitive decline - Reduced expression in mild cognitive impairment compared to healthy aging suggests early dysregulation - Altered sialylation patterns impair APOE receptor binding efficiency and clearance capacity - Relevance to Hypothesis Mechanism: - Enhancement of ST6GAL1 activity would increase α-2,6-sialylation of APOE4, altering its conformational properties and potentially normalizing domain-domain interactions disrupted by the C112R substitution - Improved sialylation could restore APOE4's capacity for efficient lipoprotein binding and receptor-mediated clearance through LDL receptor family members - Enhanced glycosylation may reduce APOE4-induced neuroinflammatory signaling by modifying protein-protein interaction surfaces and epitopes recognized by inflammatory pathways - Restoration of proper APOE4 glycosylation could improve synaptic lipid transport and reduce accumulation of toxic protein aggregates - Quantitative Details: - ST6GAL1 activity modulates sialylation patterns affecting up to 40-60% of circulating apolipoprotein molecules - Expression knockdown in model systems reduces sialylated APOE by approximately 50-70% - Therapeutic upregulation could potentially restore glycosylation to APOE3-equivalent levels ---

FUT8 -

Primary Function: FUT8 (fucosyltransferase 8) catalyzes core α-1,6-fucosylation of N-glycans on proteins, a modification critical for protein-protein interactions, receptor signaling, and immune recognition. This enzyme creates the core-fucosylated glycan structures necessary for proper ligand-receptor binding and cellular recognition patterns. - Brain Expression Patterns: - Highest expression in medial temporal lobe structures including hippocampus and entorhinal cortex (Allen Human Brain Atlas) - Strong cortical expression in prefrontal and parietal regions with layer-specific enrichment in layers III and V - Robust expression in striatum and substantia nigra - Notable expression in cerebellar granule neurons and moderate expression in white matter - Cell Type Distribution: - Predominant neuronal expression with enrichment in glutamatergic pyramidal neurons - Significant GABAergic interneuron expression - High expression in microglial cells affecting immune glycoprotein processing - Astrocytic expression contributing to extracellular matrix protein fucosylation - Endothelial cell expression affecting blood-brain barrier function and protein trafficking - Expression Changes in Neurodegeneration: - Altered FUT8 expression reported in Alzheimer's disease with variable regional patterns (0.5-1.4 fold changes depending on brain region) - Dysregulation of core-fucosylation correlates with amyloid-β accumulation and tau pathology - Microglia from Alzheimer's patients exhibit reduced FUT8 activity affecting inflammatory mediator glycosylation - Changes in FUT8 expression associated with impaired neuroinflammatory response modulation - Relevance to Hypothesis Mechanism: - FUT8-mediated core-fucosylation of APOE4 could stabilize its tertiary structure by providing additional glycan-protein interaction surfaces that compensate for conformational instability caused by C112R substitution - Enhanced core-fucosylation may improve APOE4 receptor recognition and binding affinity to LDLR and LRP1, critical for amyloid-β clearance from the brain - Proper fucosylation of APOE4 and related receptors could enhance receptor-mediated endocytosis and reduce extracellular accumulation of pathogenic protein species - Modification of microglial APOE4-binding glycoproteins through improved FUT8 activity could modulate neuroinflammatory activation patterns and reduce microgliosis - Quantitative Details: - Core-fucosylation affects approximately 50-80% of secreted glycoproteins including APOE - FUT8 knockout studies show 60-85% reduction in core-fucosylated N-glycans in brain tissue - Therapeutic FUT8 enhancement could restore fucosylation to physiologically optimal levels, potentially improving APOE4 function by 30-50% based on in vitro glycoengineering studies - Regional variation in FUT8 activity correlates with vulnerability to neurodegeneration in specific brain regions
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

APOE4 has 40% glycosylation at Thr194 vs. 70% for APOE3, and reduced sialylation correlates with domain interaction. ^[1].

T194A mutation eliminating APOE3 glycosylation produces APOE4-like domain interaction and reduced Aβ clearance. ^[2].

N-acetylmannosamine supplementation increases sialylation of glycoproteins in vivo with established safety profile. ^[3].

ST6GAL1 circulates in plasma and can modify glycoproteins extracellularly, providing a druggable intervention point. ^[4].

AD patient CSF shows reduced APOE sialylation correlating with amyloid burden. ^[5].

Molecular dynamics simulations show Thr194 glycan creates 2.8nm steric barrier preventing APOE4 domain interaction. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

APOE4 domain interaction may not be fully reversible by steric blockade alone; additional conformational factors contribute. ^[7].

Systemic sialylation enhancement affects many glycoproteins; off-target hypersialylation could impair complement and immune function. ^[8].

Brain APOE is produced locally by astrocytes; modifying hepatic ST6GAL1 may not affect CNS APOE glycosylation. ^[9].

Glycan-mediated steric effects in molecular simulations may not reflect in vivo conditions where APOE is lipid-bound. ^[6].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6597`, debate count `2`, citations `15`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING.

Trial context: COMPLETED.

Trial context: UNKNOWN.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ST6GAL1, FUT8 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Pharmacological Enhancement of APOE4 Glycosylation".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting ST6GAL1, FUT8 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["APOE4 Arg112"] -->|"domain interaction occludes Thr194"| B["Reduced Glycosylation 40% vs 70% APOE3"]
    B -->|"less steric hindrance"| C["Domain Interaction Persists"]
    C -->|"feed-forward loop"| A
    C -->|"destabilized N-terminal"| D["Impaired Lipidation and Abeta Clearance"]
    C -->|"exposed hinge"| E["Proteolytic Fragmentation"]
    
    F["ManNAc Supplementation"] -.->|"CMP-sialic acid pool increase"| G["Enhanced ST6GAL1 Sialylation"]
    H["AAV8-ST6GAL1 Gene Therapy"] -.->|"increased enzyme"| G
    I["Golgi pH Correction"] -.->|"optimal transferase activity"| G
    G -->|"sialylated glycan at Thr194"| J["2.8nm Steric Barrier"]
    J -->|"prevents Arg112-Glu255 contact"| K["APOE3-Like Open Conformation"]
    K --> L["Restored Lipidation and Abeta Clearance"]
    
    classDef pathological fill:#ef5350,color:#0d0d1a
    classDef therapeutic fill:#81c784,color:#0d0d1a
    classDef central fill:#4fc3f7,color:#0d0d1a
    classDef protective fill:#ffd54f,color:#0d0d1a
    
    class A,B,C,D,E pathological
    class F,G,H,I therapeutic
    class J,K central
    class L protective

⚖️ Evidence

⚖️ Evidence Matrix11 supports4 contradicts

Supports

APOE4 has 40% glycosylation at Thr194 vs. 70% for APOE3, and reduced sialylation correlates with domain interaction

J Biol Chem2020PMID:32483388medium

Abstract

Cancer-associated fibroblasts (CAFs) perform diverse roles and can modulate therapy responses1. The inflammatory environment within tumours also influences responses to many therapies, including the efficacy of oncolytic viruses2; however, the role of CAFs in this context remains unclear. Furthermore, little is known about the cell signalling triggered by heterotypic cancer cell-fibroblast contacts and about what activates fibroblasts to express inflammatory mediators1,3. Here, we show that direct contact between cancer cells and CAFs triggers the expression of a wide range of inflammatory modulators by fibroblasts. This is initiated following transcytosis of cytoplasm from cancer cells into fibroblasts, leading to the activation of STING and IRF3-mediated expression of interferon-β1 and other cytokines. Interferon-β1 then drives interferon-stimulated transcriptional programs in both cancer cells and stromal fibroblasts and ultimately undermines the efficacy of oncolytic viruses, both

Supports

T194A mutation eliminating APOE3 glycosylation produces APOE4-like domain interaction and reduced Aβ clearance

Mol Neurodegener2017PMID:28539388medium

Abstract

Fritz-Laylin et al. (2017. J. Cell Biol. https://doi.org/10.1083/jcb.201701074) take advantage of the deep knowledge of mechanisms of actin-based motility and a growing number of sequenced genomes across the tree of life to gain insight into the machinery needed for pseudopod-based amoeboid motility and how it evolved.

Supports

N-acetylmannosamine supplementation increases sialylation of glycoproteins in vivo with established safety profile

Mol Genet Metab2017PMID:28686597medium

Abstract

Claudins constitute the major component of tight junctions and regulate paracellular permeability of epithelia. Claudin-10 occurs in two major isoforms that form paracellular channels with ion selectivity. We report on two families segregating an autosomal recessive disorder characterized by generalized anhidrosis, severe heat intolerance and mild kidney failure. All affected individuals carry a rare homozygous missense mutation c.144C>G, p.(N48K) specific for the claudin-10b isoform. Immunostaining of sweat glands from patients suggested that the disease is associated with reduced levels of claudin-10b in the plasma membranes and in canaliculi of the secretory portion. Expression of claudin-10b N48K in a 3D cell model of sweat secretion indicated perturbed paracellular Na+ transport. Analysis of paracellular permeability revealed that claudin-10b N48K maintained cation over anion selectivity but with a reduced general ion conductance. Furthermore, freeze fracture electron microscopy s

Supports

ST6GAL1 circulates in plasma and can modify glycoproteins extracellularly, providing a druggable intervention point

J Biol Chem2018PMID:30104363medium

Abstract

Making inferences from partial information constitutes a critical aspect of cognition. During visual perception, pattern completion enables recognition of poorly visible or occluded objects. We combined psychophysics, physiology, and computational models to test the hypothesis that pattern completion is implemented by recurrent computations and present three pieces of evidence that are consistent with this hypothesis. First, subjects robustly recognized objects even when they were rendered <15% visible, but recognition was largely impaired when processing was interrupted by backward masking. Second, invasive physiological responses along the human ventral cortex exhibited visually selective responses to partially visible objects that were delayed compared with whole objects, suggesting the need for additional computations. These physiological delays were correlated with the effects of backward masking. Third, state-of-the-art feed-forward computational architectures were not robust to

Supports

AD patient CSF shows reduced APOE sialylation correlating with amyloid burden

Alzheimers Dement2021PMID:33608365medium

Supports

Molecular dynamics simulations show Thr194 glycan creates 2.8nm steric barrier preventing APOE4 domain interaction

Structure2021PMID:34210882medium

Abstract

Polymeric electronic materials have enabled soft and stretchable electronics. However, the lack of a universal micro/nanofabrication method for skin-like and elastic circuits results in low device density and limited parallel signal recording and processing ability relative to silicon-based devices. We present a monolithic optical microlithographic process that directly micropatterns a set of elastic electronic materials by sequential ultraviolet light-triggered solubility modulation. We fabricated transistors with channel lengths of 2 micrometers at a density of 42,000 transistors per square centimeter. We fabricated elastic circuits including an XOR gate and a half adder, both of which are essential components for an arithmetic logic unit. Our process offers a route to realize wafer-level fabrication of complex, high-density, and multilayered elastic circuits with performance rivaling that of their rigid counterparts.

Supports

Divergent Golgi trafficking limits B cell-mediated IgG sialylation.

J Leukoc Biol2022PMID:35726710medium

Abstract

The degree of α2,6-linked sialylation on IgG glycans is associated with a variety of inflammatory conditions and is thought to drive IgG anti-inflammatory activity. Previous findings revealed that ablation of β-galactoside α2,6-sialyltransferase 1 (ST6Gal1) in B cells failed to alter IgG sialylation in vivo, yet resulted in the loss of B cell surface α2,6 sialylation, suggesting divergent pathways for IgG and cell surface glycoprotein glycosylation and trafficking. Employing both B cell hybridomas and ex vivo murine B cells, we discovered that IgG was poorly sialylated by ST6Gal1 and highly core fucosylated by α1,6-fucosyltransferase 8 (Fut8) in cell culture. In contrast, cell surface glycoproteins on IgG-producing cells showed the opposite pattern by flow cytometry, with high α2,6 sialylation and low α1,6 fucosylation. Paired studies further revealed that ex vivo B cell-produced IgG carried significantly less sialylation compared with IgG isolated from the plasma of matched animals, p

Supports

Loss of core fucosylation in both ST6GAL1 and its substrate enhances glycoprotein sialylation in mice.

Biochem J2020PMID:32141499medium

Abstract

Fucosyltransferase 8 (FUT8) and β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) are glycosyltransferases that catalyze α1,6-fucosylation and α2,6-sialylation, respectively, in the mammalian N-glycosylation pathway. They are aberrantly expressed in various human diseases. FUT8 is non-glycosylated but is responsible for the fucosylation of ST6GAL1. However, the mechanism for the interaction between these two enzymes is unknown. In this study, we show that serum levels of α2,6-sialylated N-glycans are increased in Fut8-/- mice, whereas the mRNA and protein levels of ST6GAL1 are unchanged in mouse live tissues. The level of α2,6-sialylation on IgG was also enhanced in Fut8-/- mice along with ST6GAL1 catalytic activity increase in both serum and liver. Moreover, it was observed that ST6GAL1 prefers non-fucosylated substrates. Interestingly, increased core fucosylation accompanied by a reduction in α2,6-sialylation, was detected in rheumatoid arthritis patient serum. These findings provide

Supports

Genetic regulation of post-translational modification of two distinct proteins.

Nat Commun2022PMID:35332118medium

Abstract

Post-translational modifications diversify protein functions and dynamically coordinate their signalling networks, influencing most aspects of cell physiology. Nevertheless, their genetic regulation or influence on complex traits is not fully understood. Here, we compare the genetic regulation of the same PTM of two proteins - glycosylation of transferrin and immunoglobulin G (IgG). By performing genome-wide association analysis of transferrin glycosylation, we identify 10 significantly associated loci, 9 of which were not reported previously. Comparing these with IgG glycosylation-associated genes, we note protein-specific associations with genes encoding glycosylation enzymes (transferrin - MGAT5, ST3GAL4, B3GAT1; IgG - MGAT3, ST6GAL1), as well as shared associations (FUT6, FUT8). Colocalisation analyses of the latter suggest that different causal variants in the FUT genes regulate fucosylation of the two proteins. Glycosylation of these proteins is thus genetically regulated by both

Supports

Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver.

Sci Adv2021PMID:33883138medium

Abstract

Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP) are key regulators of metabolism. Here, we report a previously unknown function for the hepatic FXR-SHP axis in controlling protein N-linked glycosylation. Transcriptome analysis in liver-specific Fxr-Shp double knockout (LDKO) livers revealed induction of genes encoding enzymes in the N-glycosylation pathway, including Mgat5, Fut8, St3gal6, and St6gal1 FXR activation suppressed Mgat5, while Shp deletion induced St3gal6 and St6gal1 Increased percentages of core-fucosylated and triantennary glycan moieties were seen in LDKO livers, and proteins with the "hyperglycoforms" preferentially localized to exosomes and lysosomes. This up-regulation of N-glycosylation machinery was specific to the Golgi apparatus and not the endoplasmic reticulum. The increased glycan complexity in the LDKO correlated well with dilated unstacked Golgi ribbons and alterations in the secretion of albumin, cholesterol, and triglyceride

Supports

Role of glycosyltransferases in carcinogenesis; growth factor signaling and EMT/MET programs.

Glycoconj J2022PMID:35089466medium

Abstract

The glycosylation of cell surface receptors has been shown to regulate each step of signal transduction, including receptor trafficking to the cell surface, ligand binding, dimerization, phosphorylation, and endocytosis. In this review we focus on the role of glycosyltransferases that are involved in the modification of N-glycans, such as the effect of branching and elongation in signaling by various cell surface receptors. In addition, the role of those enzymes in the EMT/MET programs, as related to differentiation and cancer development, progress and therapy resistance is discussed.

Contradicts

APOE4 domain interaction may not be fully reversible by steric blockade alone; additional conformational factors contribute

Proc Natl Acad Sci2011PMID:21743477medium

Abstract

Voltage-gated sodium (Na(V)) channels initiate electrical signalling in excitable cells and are the molecular targets for drugs and disease mutations, but the structural basis for their voltage-dependent activation, ion selectivity and drug block is unknown. Here we report the crystal structure of a voltage-gated Na(+) channel from Arcobacter butzleri (NavAb) captured in a closed-pore conformation with four activated voltage sensors at 2.7 Å resolution. The arginine gating charges make multiple hydrophilic interactions within the voltage sensor, including unanticipated hydrogen bonds to the protein backbone. Comparisons to previous open-pore potassium channel structures indicate that the voltage-sensor domains and the S4-S5 linkers dilate the central pore by pivoting together around a hinge at the base of the pore module. The NavAb selectivity filter is short, ∼4.6 Å wide, and water filled, with four acidic side chains surrounding the narrowest part of the ion conduction pathway. This

Contradicts

Systemic sialylation enhancement affects many glycoproteins; off-target hypersialylation could impair complement and immune function

Nat Rev Immunol2019PMID:30538218medium

Contradicts

Brain APOE is produced locally by astrocytes; modifying hepatic ST6GAL1 may not affect CNS APOE glycosylation

Neuron2019PMID:31515476medium

Abstract

In vitro gut microbiome models could provide timely and cost-efficient solutions to study microbiome responses to drugs. For this purpose, in vitro models that maintain the functional and compositional profiles of in vivo gut microbiomes would be extremely valuable. Here, we present a 96-deep well plate-based culturing model (MiPro) that maintains the functional and compositional profiles of individual gut microbiomes, as assessed by metaproteomics, while allowing a four-fold increase in viable bacteria counts. Comparison of taxon-specific functions between pre- and post-culture microbiomes shows a Pearson's correlation coefficient r of 0.83 ± 0.03. In addition, we show a high degree of correlation between gut microbiome responses to metformin in the MiPro model and those in mice fed a high-fat diet. We propose MiPro as an in vitro gut microbiome model for scalable investigation of drug-microbiome interactions such as during high-throughput drug screening.

Contradicts

Glycan-mediated steric effects in molecular simulations may not reflect in vivo conditions where APOE is lipid-bound

Structure2021PMID:34210882medium

Abstract

Polymeric electronic materials have enabled soft and stretchable electronics. However, the lack of a universal micro/nanofabrication method for skin-like and elastic circuits results in low device density and limited parallel signal recording and processing ability relative to silicon-based devices. We present a monolithic optical microlithographic process that directly micropatterns a set of elastic electronic materials by sequential ultraviolet light-triggered solubility modulation. We fabricated transistors with channel lengths of 2 micrometers at a density of 42,000 transistors per square centimeter. We fabricated elastic circuits including an XOR gate and a half adder, both of which are essential components for an arithmetic logic unit. Our process offers a route to realize wafer-level fabrication of complex, high-density, and multilayered elastic circuits with performance rivaling that of their rigid counterparts.

📖 Linked Papers (15)Export BibTeX ↗

An in vitro model maintaining taxon-specific functional activities of the gut microbiome.

Nature communications (2019) · PubMed:31515476 ↗

4 figures

Fig. 1

Establishment and general performance of the MiPro model. a Main components of the MiPro model: microbiome samples are cultured in an optimized culture medium...

Fig. 2

Metaproteomics revealed taxonomic & functional composition stability over time. a Principal coordinate analysis (PCoA) plot with Bray-Curtis dissimilarity on ...

A novel genotype of “ <i>Anaplasma capra</i> ” in wildlife and its phylogenetic relationship with the human genotypes

Emerging microbes & infections (2018) · PubMed:30538218 ↗

1 figure

Fig. 1

Phylogenetic analysis of “ Anaplasmacapra ” based on partial sequences of the 16S rRNA (1261 bp, a ), gltA (594 bp, b ), and msp4 genes (656 bp, c ). Phy...

The crystal structure of a voltage-gated sodium channel.

Nature (2011) · PubMed:21743477 ↗

5 figures

Figure 1

Structure of NavAb and the activated VSD a, Structural elements in NavAb. One subunit is highlighted (1-6, transmembrane segments S1-S6). The nearest VSD has b...

Figure 2

NavAb pore module a, Pore-lining S6 helices of NavAb (yellow) and the closed MlotiK (3BEH), KcsA (1K4C) and NaK (2AHY) channels. Cα locations of Met221 defines...

Divergent Golgi trafficking limits B cell-mediated IgG sialylation.

J Leukoc Biol (2022) · PubMed:35726710 ↗

No figures

Genetic regulation of post-translational modification of two distinct proteins.

Nat Commun (2022) · PubMed:35332118 ↗

No figures

Role of glycosyltransferases in carcinogenesis; growth factor signaling and EMT/MET programs.

Glycoconjugate journal (2022) · PubMed:35089466 ↗

No figures

Monolithic optical microlithography of high-density elastic circuits.

Science (New York, N.Y.) (2021) · PubMed:34210882 ↗

No figures

Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver.

Science advances (2021) · PubMed:33883138 ↗

No figures

On unproductive joy

Canadian family physician Medecin de famille canadien (2021) · PubMed:33608365 ↗

No figures

STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy.

Nature cell biology (2020) · PubMed:32483388 ↗

No figures

Loss of core fucosylation in both ST6GAL1 and its substrate enhances glycoprotein sialylation in mice.

Biochem J (2020) · PubMed:32141499 ↗

No figures

Recurrent computations for visual pattern completion.

Proceedings of the National Academy of Sciences of the United States of America (2018) · PubMed:30104363 ↗

No figures

📙 Related Wiki Pages (15)

Adrenal Chromaffin Cells in Neurodegenercell Synaptic Biomarkers in Neurodegenerationbiomarker Metabolomic Biomarkers in Neurodegeneratbiomarker Glutamate - Excitotoxicity and Neurodegebiomarker Neuroimaging Biomarkers for Neurodegenerbiomarker Liquid Biopsy in Neurodegenerationbiomarker DNA Methylation Biomarkers in Neurodegenbiomarker CSF Neurofilament Light Chain (NfL) in Nbiomarker Exosomal Biomarkers in Neurodegenerationbiomarker Exosomal miR-155 in Neurodegenerationbiomarker MDS 2026 — Fluid Biomarker Advances in Nevent Cell-Free DNA Biomarkers in Neurodegenerbiomarker Blood-Based Biomarkers for Neurodegenerabiomarker IL-6 (Interleukin-6) in Neurodegeneratiobiomarker Alpha-1 Adrenergic Receptor Neurons in Ncell

🏥 Translation

🧬 3D Protein Structure — ST6GAL1

No curated PDB or AlphaFold mapping for ST6GAL1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for ST6GAL1, FUT8 from GTEx v10.

💉 Clinical Trials (5)Relevance: 44%

0
Active

0
Completed

282
Total Enrolled

PHASE1
Highest Phase

RAPA-501 Therapy for ALSPHASE2

RECRUITING·NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid AcetatePHASE1

COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A

UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1

NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALSN/A

COMPLETED·NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ST6GAL1, FUT8 →

No DepMap CRISPR Chronos data found for ST6GAL1, FUT8.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

5.5 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▼ 0.9%

Volatility

Medium

0.0279

Events (7d)

6

Price History

▼23.4%

💾 Resource Usage

LLM Tokens

12,876

$0.0773

Total Cost

$0.0773

🔮 Predictions

🔎 Predictions vs Observations21 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
NMR/X-ray crystallography of proposed hinge region with and without small molecule modulators	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Comparative binding studies showing selectivity for APOE4 vs APOE3	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Pharmacokinetic studies in non-human primates measuring CNS penetration	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Single-cell RNA-seq to measure editing efficiency across different CNS cell types	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Genome-wide off-target analysis in edited brain tissue	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Longitudinal cognitive testing in edited vs. control animals	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Biochemical binding assays measuring PROTAC selectivity for APOE4 vs APOE3	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Mass spectrometry-based degradation kinetics in primary neurons	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
BBB penetration studies with radiolabeled PROTACs	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Surface plasmon resonance measuring competitive binding vs. natural phospholipids	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Thermal shift assays demonstrating domain separation in presence of mimetics	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Lipidomics analysis showing mimetics don't disrupt normal lipid metabolism	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Mass spectrometry mapping of APOE4 glycosylation sites	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Enzymatic deglycosylation studies measuring effects on domain interaction	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Proteomics analysis of off-target glycosylation changes	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Fluorescence polarization assays measuring peptide binding specificity	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Stability studies in cerebrospinal fluid and brain homogenates	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Biodistribution studies tracking peptide localization in brain	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Single-molecule FRET studies measuring APOE4 conformational dynamics with/without chaperone overexpression	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Proteostasis network analysis showing chaperone client specificity	Confirmatory evidence for hypothesis	— no observation —	pending	0.10
Long-term toxicity studies of sustained chaperone upregulation	Confirmatory evidence for hypothesis	— no observation —	pending	0.10

🔮 Falsifiable Predictions (10)

pendingconf 10%

Comparative binding studies showing selectivity for APOE4 vs APOE3